Advertisement

OGN

Organon & Co.

Healthcare · USD

Set alert

Price alert · OGN

All alert types
13.84 USD +0.03 +0.22%
As of Oct 30, 2026 Extended hours 13.84 0.00%
Bid
13.83 × 34,600
Ask
13.84 × 13,800
13.81 Day range 13.84
5.70 52-week range 13.84
YTD
+93.03%
1 year
+110.65%
Open
13.83
Prev close
13.81
Mkt cap
3.63B
Vol
1.85M
Avg vol
2.59M
EPS
0.78
P/E
17.74
Div yield
0.58%
More statistics
Low
13.81
High
13.84
Forward P/E
3.79
Beta
1.54
Short ratio
8.54
Inst. own
84.60%
Dividend
0.08
Ex-div date
Aug 13, 2026
50-d avg
13.74
200-d avg
11.49
1y target
10.33

5D chart

Chart tools
Interval
OGN five-day price chart13.713.813.813.813.8Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Market cap
3.63B
Enterprise value
11.05B
Trailing P/E
17.74
Forward P/E
3.79
PEG ratio
0.00
Price / sales
0.59
Price / book
3.61
EPS (TTM)
0.78
Beta
1.54
Dividend yield
0.58%
Payout ratio
10.26%
Profit margin
3.41%
Revenue (TTM)
6.13B
Revenue growth
-2.30%
Free cash flow
490.75M
Total cash
1.13B
Total debt
8.55B
Return on equity
24.04%
Shares outstanding
262.61M
Short % of float
8.15%
50-day average
13.74
200-day average
11.49

Analyst view

Consensus: hold

Hold
Price target (mean) 10.33 -25.3% downside
Target (low)
8.00
Target (mean)
10.33
Target (high)
14.00
Ratings (0m) 4 0 buy · 3 hold · 1 sell
  • Strong buy0
  • Buy0
  • Hold3
  • Sell0
  • Strong sell1

Next earnings

Consensus EPS estimate 0.94645.

Earnings history

Financials — quick view

All financials
OGN Revenue — quarterly 1.56B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
OGN Net income — quarterly 108.00M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
OGN EPS — quarterly 0.41
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

OGN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Oct 30, 2026Sep 30, 20260.880.94+0.06+6.82%
Jul 31, 2026Jun 30, 20260.850.850.000.00%
Apr 30, 2026Mar 31, 20260.830.71-0.12-14.46%
Feb 12, 2026Dec 31, 20250.730.63-0.10-13.70%
Nov 10, 2025Sep 30, 20250.931.01+0.08+8.60%
Aug 5, 2025Jun 30, 20250.941.00+0.06+6.38%

Upgrades / downgrades

OGN analyst upgrades and downgrades
DateFirmActionFromTo
Apr 29, 2026BNP ParibasdownOutperformNeutral
Apr 28, 2026Piper SandlerupUnderweightNeutral
Feb 24, 2026BarclaysmainUnderweightUnderweight
Dec 9, 2025Barclaysinit—Underweight
Nov 11, 2025JP MorganmainUnderweightUnderweight
Nov 11, 2025Morgan StanleymainEqual-WeightEqual-Weight

About Organon & Co.

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Website
organon.com

News

Your note

Sign in to keep a note on OGN — it syncs with the Stock Master app.

Insider holders

OGN insider holders
InsiderRelationLatest transactionDateShares held
ALI KEVINChief Executive OfficerPurchaseMay 4, 2025282,731
COX CARRIE SMITHOfficer and DirectorPurchaseNov 11, 20250
FALCIONE AARONOfficerConversion of Exercise of derivative securityMar 30, 2026101,431
HOLZBAUR LYNETTEOfficerPurchaseMay 5, 202652,850
KARP DANIELOfficerConversion of Exercise of derivative securityMar 30, 202669,547
MORRISSEY JOSEPH T JRChief Executive OfficerConversion of Exercise of derivative securityMar 30, 2026123,123

Institution ownership

OGN institution ownership
Holder% heldSharesValueReported
Blackrock Inc.12.21%32,056,866443.67MJun 29, 2026
Pentwater Capital Management Lp6.89%18,100,000250.50MJun 29, 2026
Vanguard Portfolio Management LLC5.76%15,132,118209.43MJun 29, 2026
Vanguard Capital Management LLC4.54%11,909,865164.83MJun 29, 2026
State Street Corporation3.68%9,659,371133.69MJun 29, 2026
Goldman Sachs Group Inc1.98%5,199,00271.95MJun 29, 2026

Fund ownership

OGN fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF5.95%15,638,261216.43MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%8,332,789115.33MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.29%6,024,69983.38MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund1.45%3,815,00152.80MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.15%3,010,25541.66MJun 29, 2026
NexPoint Funds I-NexPoint Merger Arbitrage Fund1.03%2,705,08037.44MJun 29, 2026
Advertisement